Figure 6
From: IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling
IL-17A increases retinal ganglion cell apoptosis in Akita mice via Act1 signaling. The treatment time periods of IL-17A, Ad-Act1-shRNA and anti-IL-17A mAb were the same as described in Figure 4. (a) Immunofluorescent staining of retinal cross-sections indicates NeuN/TUNEL double-positive cells in the GCL. (b) Immunofluorescent staining of retinal cross-sections indicates NeuN/Active-Cas (Active-caspase-3) double-positive cells in the GCL. The arrows in (a, b) indicate representative double-labeled cells. (c) Statistical histogram for (a, b). The data were obtained as described in the Materials and methods. (d) Caspase-3 activity in the retina that was determined by the ratio of active-caspase-3 (Active-Cas) and pro-caspase-3 (Pro-Cas). **P<0.01 vs wild-type (WT) mice; ++P<0.01 vs Akita mice or Akita+PBS; &&P<0.01 vs Akita+Ad-GFP; NS (no significance) vs Akita. Ad-Act1-shRNA, adenoviral vector that expressed short hairpin RNA targeting Act1; Ad-GFP, adenoviral vector that expressed green fluorescent protein; GCL, ganglion cell layer; IL, interleukin; mAb, monoclonal antibody; TUNEL, TdT-mediated dUTP nick end labeling.
